Tuesday, November 10, 2015
The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health, has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation. These diseases are difficult for doctors to diagnose because they are rarely seen, have not previously been described or are unrecognized forms of more common diseases.
Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center‘s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological Clinical Research Institute have launched an amyotrophic lateral sclerosis (ALS) research project: Answer ALS is the largest single coordinated and comprehensive effort to end ALS.
To further strengthen the nation’s infectious disease response capability, the U.S. Department of Health and Human Services has selected nine health departments and associated partner hospitals to become special regional treatment centers for patients with Ebola or other severe, highly infectious diseases.
Juniper Pharmaceuticals, a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health, has created a scientific advisory board (SAB) comprised of international physicians and scientists whose mission will be to provide scientific and clinical advice on the identification and advancement of product candidates for Juniper’s women’s health portfolio.
The ALS Association, Harvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In parallel testing, brain cells will be made from each patient’s stem cells to see if they can predict which patients might respond to the medicine.